Dual anti-platelet therapy remains a cornerstone of the treatment for coronary artery disease. When choosing a second anti-platelet, ticagrelor remains a principal agent after the recent PLATO trial ...
Camber expanded its team by 12%, filed 40 ANDAs and received 43 ANDA approvals in 2025. 2025 was a year filled with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback